Jeffrey Fowler, DO
Interventional Cardiology · Pittsburgh, PANPI 1497998090
Payments from drug & device makers
Across 455 payments — averaging $60.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Abiomed$5K
- Edwards Lifesciences$4K
- Boston Scientific$2K
- Medtronic$952
- Shockwave Medical, Inc$928
- plus $2K from 21 others
What the payments were for
- Consulting fees$2,3759%
- Travel & lodging$7,43028%
- Food & beverage$16,61263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 207 | $12,317 |
| Abiomed | 36 | $4,625 |
| Edwards Lifesciences | 58 | $4,250 |
| Boston Scientific | 35 | $2,325 |
| Medtronic | 18 | $952 |
| Shockwave Medical, Inc | 26 | $928 |
| Inari Medical, Inc. | 3 | $383 |
| Amgen | 10 | $244 |
| Stryker | 6 | $206 |
| Recor Medical Inc | 2 | $193 |
| Acist Medical Systems, Inc. | 3 | $177 |
| AstraZeneca | 4 | $146 |
| E.r. Squibb & Sons, L.L.C. | 6 | $110 |
| Cvrx, Inc. | 7 | $105 |
| W. L. Gore & Associates, Inc. | 5 | $104 |
| Boehringer Ingelheim | 4 | $95 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $88 |
| Heartflow, Inc. | 3 | $69 |
| Cardiovascular Systems Inc. | 7 | $67 |
| Novartis | 3 | $56 |
| Livanova USA, Inc. | 1 | $40 |
| Impulse Dynamics (USA) Inc. | 1 | $39 |
| Cardiva Medical, Inc. | 2 | $34 |
| Philips North America LLC | 1 | $31 |
| Terumo Medical Corporation | 1 | $29 |
| Teleflex LLC | 1 | $28 |
| Angiodynamics, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAVITOR$2,848
- Impella$2,152
- MitraClip$1,875
- Mitra Clip system$1,809
- EVOQUE$1,566
- Edwards SAPIEN 3 Transcatheter Heart Valve$787
- COREVALVE EVOLUT R$625
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$573
- Xience Sierra Coronary Stent System$479
- Dragonfly OCT$426
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$347
- WATCHMAN Access System$343
- MitraClip System$329
- CT THROMBECTOMY SYSTEM KIT$319
- FLOWTRIEVER CATHETER, S$319
- Watchman$262
- SAPIEN 3 Ultra RESILIA$234
- CVI SYSTEMS$174
- Ultreon$172
- PARADISE RENAL DENERVATION SYSTEM$162
How this compares
$27,667 in reported general payments places this provider in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $112,422 |
| JardianceEmpagliflozin | 109 | $110,492 |
| EntrestoSacubitril/Valsartan | 64 | $75,280 |
| FarxigaDapagliflozin Propanediol | 42 | $43,426 |
| XareltoRivaroxaban | 27 | $31,260 |
| Repatha SureclickEvolocumab | 11 | $17,665 |
| BrilintaTicagrelor | 18 | $13,193 |
| Atorvastatin Calcium | 142 | $2,081 |
| Metoprolol Succinate | 163 | $2,004 |
| Rosuvastatin Calcium | 78 | $1,669 |
| Valsartan | 53 | $1,345 |
| Carvedilol | 103 | $1,232 |
| Losartan Potassium | 99 | $1,124 |
| Ezetimibe | 35 | $909 |
| Lisinopril | 86 | $732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $95 | $110,492109 claims |
| NovartisEntresto | $56 | $75,28064 claims |
| AstraZenecaFarxiga, Brilinta | $146 | $56,61960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Pittsburgh
- Ramzi KhalilPittsburgh$1.6M
- David LasordaPittsburgh$1.1M
- Catalin TomaPittsburgh$522K
- Anson SmithPittsburgh$518K
- Saad TabbaraPittsburgh$355K
- Suresh MulukutlaPittsburgh$260K
- Ryan ZuzekPittsburgh$152K
- Dustin KlinerPittsburgh$93K
- Mithun ChakravarthyPittsburgh$79K
- William GrayWynnewood$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.